A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 294 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer January 3, 2024 The First Report from the Cancer Programme of the 100,000 Genomes... January 16, 2024 New study to investigate breast cancer in ethnic minority groups July 11, 2023 Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal... April 6, 2021 Load more HOT NEWS Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam,... Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... Join the Great American Smokeout for a Healthier Tomorrow A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in...
